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As a result of superior efficacy and overall tolerability, atypical antipsychotic drugs have become the treatment of choice for schizophrenia
and related disorders, despite their side effects. Weight gain is a common and potentially serious complication of some antipsychotic drug
therapy, and may be accompanied by hyperlipidemia, hypertension and hyperglycemia and, in some extreme cases, diabetic ketoacidosis.
The molecular mechanism(s) responsible for antipsychotic drug-induced weight gain are unknown, but have been hypothesized to be
because of interactions of antipsychotic drugs with several neurotransmitter receptors, including 5-HT2A and 5-HT2C serotonin
receptors, H1-histamine receptors, a1- and a2-adrenergic receptors, and m3-muscarinic receptors. To determine the receptor(s) likely to
be responsible for antipsychotic-drug-induced weight gain, we screened 17 typical and atypical antipsychotic drugs for binding to 12
neurotransmitter receptors. H1-histamine receptor affinities for this group of typical and atypical antipsychotic drugs were significantly
correlated with weight gain (Spearman r¼0.72; po0.01), as were affinities for a1A adrenergic (r¼0.54; po0.05), 5-HT2C
(r¼0.49; po0.05) and 5-HT6 receptors (r¼0.54; po0.05), whereas eight other receptors’ affinities were not. A principal
components analysis showed that affinities at the H1, a2A, a2B, 5-HT2A, 5-HT2C, and 5-HT6 receptors were most highly correlated with
the first principal component, and affinities for the D2, 5-HT1A, and 5-HT7 receptors were most highly correlated with the second
principal component. A discriminant functions analysis showed that affinities for the H1 and a1A receptors were most highly correlated
with the discriminant function axis. The discriminant function analysis, as well as the affinity for the H1-histamine receptor alone, correctly
classified 15 of the 17 drugs into two groups; those that induce weight gain and those that do not. Because centrally acting H1-histamine
receptor antagonists are known to induce weight gain with chronic use, and because H1-histamine receptor affinities are positively
correlated with weight gain among typical and atypical antipsychotic drugs, it is recommended that the next generation of atypical
antipsychotic drugs be screened to avoid H1-histamine receptors.
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Atypical antipsychotic drugs, characterized by relatively
high affinities for 5-HT2A serotonin receptors and lower
affinities for D2-dopamine receptors (Meltzer et al, 1989),
include clozapine, olanzapine, risperidone, quetiapine, and
ziprasidone, and have been of considerable value in the
treatment of schizophrenia (Meltzer, 1999a). The proto-
typical atypical antipsychotic drug clozapine has become
the treatment of choice for treatment-resistant and treat-
ment-intolerant schizophrenia and related disorders be-
cause of its greater efficacy (Kane et al, 1988; Meltzer et al,
1989) and lack of extrapyramidal sideeffects. Clozapine
treatment also substantially decreases suicidality among
patients with schizophrenia (Meltzer, 1999b; Meltzer and
Okayli, 1995), and it may improve negative symptoms,
cognition, and tardive dyskinesia. Other atypical antipsy-
chotic drugs (eg olanzapine, risperidone, quetiapine, and
ziprasidone) have also been reported to improve cognition,
negative symptoms, and minimize the risks of tardive
dyskinesia, when compared with typical antipsychotic drugs
(Meltzer and McGurk, 1999; Meltzer et al, 1999).Received 18 April 2002; accepted 8 July 2002
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Atypical antipsychotic drugs may also have serious side
effects, including sedation, orthostasis, constipation and, in
the case of clozapine, a substantial risk of agranulocytosis.
Several studies have now demonstrated that a number of
typical and atypical antipsychotic drugs may induce both
short- and long-term weight gain (Taylor and McAskill,
2000; McIntyre et al, 2001; Wetterling, 2001). Recently, the
related side effects of hyperlipidemia, hyperglycemia, and
hypertension have attracted considerable attention. In fact,
a recent study (Fontaine et al, 2001) suggested that the
magnitude of weight gain and its attendant increases in
morbidity and mortality may greatly diminish the positive
effects of those atypical antipsychotic drugs that produce
these effects to the greatest extent, that is, olanzapine and
clozapine.
The mechanism(s) responsible for antipsychotic-drug-
induced weight gain are not understood. Altered glucose
homeostasis and metabolism as well as increased food
intake have been proposed as mechanisms responsible
for antipsychotic-drug-induced weight gain. Typical and
atypical antipsychotic drugs have a complex pharmacology,
interacting with a number of serotonergic (eg 5-HT1A,
5-HT2A, 5-HT2C, 5-HT6 and 5-HT7 (Roth et al, 1992,
1994, 1998), dopaminergic (eg D2, D3, and D4 (Seeman
and Lee, 1975; Seeman et al, 1997; Van Tol et al, 1991),
histaminergic (eg H1 (Peroutka et al, 1980) and H4
(Nguyen et al, 2001)), adrenergic, and muscarinic
acetylcholine receptors (Bolden et al, 1992; Zeng et al,
1997). In mice, targeted deletion of some of these receptors
can have effects on body weight; for example, 5-HT2C
receptor knockout mice are obese (Tecott et al, 1995),
whereas m3-muscarinic receptor knockout mice are lean
(Yamada et al, 2001). The results with 5-HT2C receptor and
m3-muscarinic receptor knockout mice imply that the
interactions of antipsychotic drugs with these receptors
may be responsible for weight gain. Others have suggested
that interactions of typical and atypical antipsychotic drugs
with H1-histamine receptors, or their relative affinities for
the D2 and 5-HT2A receptors, may be responsible for
antipsychotic-drug-induced weight gain (eg see Wetterling,
2001).
To determine which receptor(s) are most likely
to be responsible for antipsychotic-drug-induced
weight gain, we determined the affinities of 17 selected
typical and atypical antipsychotic drugs for 12 human
or rodent cloned receptors using the resources of the
National Institute of Mental Health Psychoactive Drug
Screening Program (NIMH-PDSP). We then attempted
to correlate these receptor affinities with short-term
weight gain data derived from a previous meta-analysis
of the literature (Allison et al, 1999). The most robust
predictor of a drug’s propensity to induce weight
gain was its affinity for the H1 histamine receptor. Our
findings predict that newer atypical antipsychotic drugs
that have low H1-histamine receptor affinities (eg
ziprasidone, aripiprazole) will have low weight gain
liabilities. These results also suggest that centrally active
drugs with relatively higher H1-histamine receptor
affinities should be used with caution because of the
propensity of these drugs to induce weight gain and the




Typical and atypical antipsychotic drugs were obtained as
previously described (Rauser et al, 2001), with the following
exceptions: molindone was obtained from Research Diag-
nostics, Inc. (Flanders, NJ), whereas aripiprazole was a kind
gift of Richard Mailman (University of North Carolina,
Chapel Hill, NC). Cloned receptor preparations were
obtained via the resources of the NIMH-PDSP as previously
detailed (Rothman et al, 2000), with the exception of the
human H1-histamine receptor, which was cloned via PCR
amplification of ‘Quick-Clone’ human cDNA (Clontech)
and subcloned via NotI adaptors into the pUNIV-SIG
expression vector (Kroeze Roth, unpublished vector se-
quence). The entire coding region was sequenced by
automated dsDNA sequencing (Cleveland Genomics, Cleve-
land, OH) to verify that PCR-induced mutations had not
occurred.
Radioligand Binding Assays
All binding assays were as previously described (Glennon et
al, 2000; Rothman et al, 2000), primarily using cloned
human receptor preparations. On-line protocols are avail-
able at http://pdsp.cwru.edu. Initial screening assays were
performed at 10 mM concentration with quadruplicate
determinations, and the percent inhibition of total specific
binding was quantified. For drugs that caused 450%
inhibition at 10 mM, full dose–response studies were
performed using drug concentrations spanning 5–6 orders
of magnitude. Typically, specific binding represented
490% of total binding. Ki values were calculated using
GraphPad Prism (GraphPad Software, San Diego, CA, USA).
All Ki values represent the mean of 3–4 separate determina-
tions.
Statistical Analysis
Short-term weight gain data were derived from a meta-
analysis of the literature (Allison et al, 1999). For all
receptor–drug pairs, binding affinities (Ki’s) in nanometers
were converted to their log values; a maximum Ki of
10 000 nM (log Ki¼ 4.0) was used for low-affinity interac-
tions. All statistical analyses were carried out with the
XLstat version 5.0 add-on package to Microsoft Excel from
Addinsoft (Paris, France). For all analyses, P-values of less
than 0.05 were considered significant.
RESULTS
Typical and Atypical Antipsychotic Drugs have a
Complex Pharmacology
Initial screening assays were performed with a large number
of typical and atypical antipsychotic drugs. In preliminary
studies, we discovered that selected typical and atypical
antipsychotic drugs interacted with virtually every biogenic
amine receptor tested, in confirmation of many prior
studies (see on-line database at http://pdsp.cwru.edu/
pdsp.asp for comparison with published studies). We
therefore narrowed our studies to a selected group of
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biogenic amine receptors that have been most closely linked
with weight gain or loss.
Comparison of Weight Gain with Selected Biogenic
Amine Receptor Affinities
Since reliable weight gain data are available for only a subset
of antipsychotic drugs (Allison et al, 1999), we more closely
examined this set of drugs, which includes both typical and
atypical antipsychotics. The typical antipsychotic drugs
chosen for study were chlorpromazine, perphenazine,
trifluoperazine, thioridazine, thiothixene, fluphenazine,
haloperidol, molindone, and pimozide. The atypical anti-
psychotic drugs chosen were clozapine, olanzapine, lox-
apine, sertindole, risperidone, ziprasidone, quetiapine, and
aripiprazole. Of importance for the present study, the
typical antipsychotic drugs tested included those reported
to induce substantial weight gain (chlorpromazine, perphe-
nazine, thioridazine, thiothixene), those that induce little
weight gain (fluphenazine, haloperidol), and those reported
to induce weight loss (molindone, pimozide) in short-term
studies (see Allison et al, 1999). Additionally, the atypical
antipsychotic drugs included those that are reported to
induce substantial weight gain in short-term studies
(clozapine, olanzapine, quetiapine), those that induce
moderate weight gain (risperidone), and those reported to
induce minimal weight gain in short-term studies (ziprasi-
done, aripiprazole). We then examined the affinities of these
receptors at a subset of 12 cloned biogenic amine receptors.
As can be seen graphically in Figure 1, and in Table 1, the
tested drugs had a relatively complex pharmacology with
substantial affinities for nearly all tested receptors. For the
most part, high H1-histamine receptor affinities were
associated with drugs that cause weight gain, whereas drugs
that induce little or no weight gain had low H1-histamine
receptor affinities. It is interesting to note that three atypical
antipsychotic drugs that do not induce substantial short-
term weight gain (ziprasidone, aripiprazole, risperidone)
have relatively high affinities for 5-HT2C serotonin recep-
tors, in confirmation of recent studies showing that two of
these drugs (risperidone, ziprasidone) are potent 5-HT2C
inverse agonists (Rauser et al, 2001). These results imply
that neither 5-HT2C receptor affinity nor 5-HT2C receptor
inverse agonist activity reliably predicts atypical antipsy-
chotic drug-induced weight gain.
The Spearman correlation coefficients (a two-tailed
nonparametric test was used, since the data deviate
significantly from normality) of the relationship between
the propensity of the drugs examined to induce weight gain
and their affinities at the 12 receptors tested are given in
Table 2. For 10 of 12 receptors, there was a negative
relationship between Ki and weight gain; for the D2 and 5-
HT7 receptors, there was a positive correlation between Ki
values and weight gain. Only the correlations between
weight gain and H1, a1A, 5-HT2C, and 5-HT6 receptor
affinities were statistically significant.
It has been amply demonstrated that the ratio of an
antipsychotic drug’s affinity for the 5-HT2A and the D2
receptors is predictive of its atypicality (Meltzer et al, 1989).
We therefore examined the relationship between the
propensity of drugs to induce weight gain and the ratio of
affinities for the various receptors tested and the affinity for
the D2 receptor (Table 3). When analyzed in this fashion,
the affinities of eight of the 11 receptors examined were
correlated to weight gain; however, the strongest relation-
























































































































Figure 1 Surface plot of affinities of 17 typical and atypical antipsychotic drugs for 12 receptors. Drugs are in order of their propensity to induce weight
gain, from the least on the left to the most on the right.
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Interestingly, no association was evident correlating weight
gain with 5-HT2A/D2 affinity ratios, as has been recently
suggested by others (eg Wetterling, 2001). In subsequent
analyses, only the log Ki values, and not the ratio data, were
used.
In order to examine the data more fully, a principal
components analysis was performed (Table 4 and Figure 2).
Initially, it was observed that there was a statistically
significant relationship among many of the receptor
affinities; this led to the computation of a correlation
matrix based on the nonparametric Spearman correlation
coefficient (Table 4). Because many of the variables studied
were significantly correlated, a principal components
analysis, which essentially ‘uncorrelates’ a set of correlated
variables, was carried out. As can be seen in Figure 2, the 17
drugs studied could be segregated by this analysis into those
that induce considerable weight gain and those that induce
little or no weight gain. Drugs that induce weight gain
tended to have low values on principal component 1, and
high values on principal component 2. Principal component
1 explained 40% of the total variation in the data matrix,
and principal component 2 explained an additional 18%.
Principal components are composites of all the variables in
a data matrix, and are mutually orthogonal in multi-
dimensional space; the contributions of the variables to
each principal component are weighted in such a fashion as
to make them mutually orthogonal. The variables most
closely correlated with principal component 1 were the
affinities at the H1, a2A, a2B, 5-HT2A, 5-HT2C, and 5-HT6
receptors, and with principal component 2 they were weight
gain and affinities for the D2, 5-HT1A, and 5-HT7 receptors
(data not shown).
The preceding analysis suggested that it might be possible
to separate the drugs studied into two groups, those with a
propensity to induce weight gain and those lacking this
propensity, based on their affinities for particular receptors.
Table 1 Weight gain and binding data for typical and atypical antipsychotic drugs as used in this study
Weight gain
Ki (nM)
Drug Classa (kg/10 weeks)b 5-HT2C 5-HT2A D2 H1 M3 a1A a2A a2B a2C 5-HT1A 5-HT6 5-HT7
Aripiprazole A 0.71 22.4 8.7 0.66 29.7 4677 26 74 102 37 5.57 783.2 9.6
Chlorpromazine T 2.1 25 8 4 6 47 0.28 184 27 46 116.4 20.1 35.8
Clozapine A 4 17 5.4 256 1.2 25 1.64 142 26 34 104.8 17 17.9
Fluphenazine T 0.43 1386 30 0.54 21 1441 6.5 314.1 81.6 28.8 145.7 38 8
Haloperidol T 0.48 10000 53 4 1800 10000 12 1130 480 550 1202 3666 377.2
Loxapine A 0.75 9.5 7.7 12 7 122 31 150.8 107.6 79.9 2456 32.9 87.2
Molindone T 1.06 10000 320 63 2130 10000 2612 1097 557.8 172.6 3797 1008 3053
Olanzapine A 3.51 6.8 2 34 2 105 115 314.1 81.6 28.8 2063 6.28 105.4
Perphenazine T 2.79 132 5.6 1.4 8 1848 10 810.5 104.9 85.2 421 17 23
Pimozide T 3.53 3350 19 0.65 692 1955 197.7 1593 821.1 376.5 650 71 0.5
Quetiapine A 2.61 2502 101 245 11 10000 22 3630 746.6 28.7 431.6 1865 307.2
Risperidone A 1.67 35 0.17 6.5 15 10000 5 150.8 107.6 1.3 427.5 1188 6.6
Sertindole A 2.94 0.9 0.58 9.1 130 2692 1.8 640 450 450 280 5.4 28
Thioridazine T 2.81 60 10 11 19 43 5 134.3 341.3 74.8 180.7 57.1 99
Thiothixene T 2.81 1400 50 0.63 4 10000 11 79.9 50.2 51.9 410.4 208.4 15.5
Trifluoperazine T 0.34 378 13 1.3 63 1001 24 653.7 163.6 391.5 950 118 290.8
Ziprasidone A 0.28 13 0.3 9.7 43 10000 18 160 48 59 76 60.9 6.62
aA, atypical; T, typical. bData from Allison et al (1999, p 24) for later classification purposes, values in bold face were coded as ‘no weight gain’ and values in normal type
were coded as ‘weight gain’.
Table 2 Correlation between propensity of 17 drugs to induce















Table 3 Correlation between propensity of 17 drugs to induce
weight gain and the ratio of the affinity for 11 receptors to the
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To further investigate this possibility, a discriminant
functions analysis was carried out (Figure 3). This type of
analysis maximizes the separation between two a priori
groups, and determines which of the variables contribute
most to this separation. This is then followed by an a
posteriori reclassification of the groups to test whether the
discriminant function can, in fact, adequately separate the
two a priori groups. In order to exclude the trivial outcome
that the weight gain data themselves would be the best
predictor of the propensity to induce weight gain, weight
gain data were excluded from this analysis. From Figure 3, it
is clear that the drugs that induce weight gain can be
discriminated from those that do not based only on receptor
affinities. The variables most highly correlated to the
discriminant axis were the affinities for the H1, and a1A
receptors (Table 5). In the a posteriori reclassification of the
drugs, loxapine and fluphenazine, which do not induce
weight gain, were classified with the group of drugs that
does induce weight gain. Thus, 15 of 17 drugs (88.2%) were
correctly classified by the discriminant functions analysis.
We then attempted to classify the drugs by their affinities
for individual receptors; only the H1 receptor affinities
correctly classified as many as 15 of the 17 drugs, with
loxapine and sertindole being misclassified. For loxapine,
this could be a reflection of how the weight gain data were
extracted from the study of Allison et al (1999), or possibly
Table 4 Correlation matrix based on Spearman’s nonparametric coefficient showing correlation between all
pairs of variables examined
Wt. gain D2 H1 a1A a2A a2B a2C 5-HT1A 5-HT2A 5-HT2C 5-HT6 5-HT7 m3
Wt gain 1.00
D2 0.36 1.00
H1 0.72 0.23 1.00
a1A 0.54 0.03 0.35 1.00
a2A 0.37 0.06 0.049 0.34 1.00
a2B 0.36 0.07 0.67 0.45 0.66 1.00
a2C 0.32 0.18 0.63 0.20 0.38 0.46 1.00
5-HT1A 0.21 0.23 0.21 0.61 0.56 0.60 0.33 1.00
5-HT2A 0.37 0.19 0.34 0.37 0.40 0.47 0.21 0.34 1.00
5-HT2C 0.49 0.31 0.43 0.26 0.51 0.51 0.22 0.34 0.85 1.00
5-HT6 0.52 0.13 0.44 0.33 0.18 0.45 0.03 0.23 0.57 0.71 1.00
5-HT7 0.11 0.49 0.11 0.22 0.39 0.37 0.30 0.57 0.46 0.22 0.14 1.00
m3 0.41 0.15 0.48 0.29 0.27 0.36 0.06 0.16 0.27 0.44 0.71 0.06 1.00
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Figure 2 Principal components analysis of weight gain and receptor affinity data. Drugs that induce weight gain are shown in bold face. The horizontal axis
is the first principal component, which explains 41% of the total variance in the data matrix, and the vertical axis is the second principal component, which
explains 17% of the total variance in the data matrix.
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the relatively small sample size for loxapine in that study.
Taken together, however, our analysis suggests that receptor
binding affinities can predict a drug’s propensity to induce
weight gain, and that the affinity for the H1-histamine
receptor is the best single predictor of that propensity.
DISCUSSION
The major finding of this paper is that H1-histamine
receptor affinity is significantly correlated with short-term
weight gain when a large number of typical and atypical
antipsychotic drugs are examined. These results imply that
antipsychotic drugs with relatively high H1 receptor
affinities are likely to induce short-term weight gain. These
results also suggest that the next generation of atypical
antipsychotic drugs should be screened for H1-histamine
receptor affinities and that drugs with relatively high H1-
histamine receptor affinities should be avoided. It has been
known for several decades that (1) centrally active drugs
with high affinities for H1-histamine receptors can induce
weight gain, (2) some antipsychotic drugs are potent H1-
histamine receptor antagonists, and (3) antipsychotic drugs
can induce weight gain. Thus, it is perhaps not surprising
that H1-histamine receptor affinities predict weight gain for
both selected typical and atypical antipsychotic drugs. What
is surprising, however, is that H1 receptor affinity was the
only variable that reliably predicted weight gain for the
typical and atypical antipsychotic drugs tested.
Several lines of evidence have suggested, in fact, that
other receptors might be responsible for atypical antipsy-
chotic-drug-induced weight gain, particularly the 5-HT2C
receptor. Thus, for instance, mice with targeted deletions of
the 5-HT2C receptor are obese (Tecott et al, 1995).
Additionally, many typical and atypical antipsychotic drugs
have high 5-HT2C receptor affinities (Canton et al, 1990;
Roth et al, 1992), and many antipsychotic drugs are potent
5-HT2C inverse agonists (Herrick-Davis et al, 2000; Rauser
et al, 2001). Finally, 5-HT2C knockout mice are resistant to
the anorectic effects of fenfluramine (Vickers et al, 1999),
although chronic administration of potent and selective 5-
HT2C antagonists does not induce weight gain in rats (Wood
et al, 2001). The present study clearly demonstrates that 5-
HT2C affinity does not predict weight gain among this group
of typical and atypical antipsychotic drugs. However, this
does not rule out the possibility that polymorphisms of the
5-HT2C receptor (Lappalainen et al, 1995; Reynolds et al,
2002), or that altered expression of various editing isoforms
of the 5-HT2C receptor (Burns et al, 1997), might
differentially contribute to variations in weight gain for
individual subjects. Indeed a recent study (Reynolds et al,
Discriminant functions analysis of log data
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Figure 3 Discriminant function analysis of weight gain and receptor affinity data. The axis represents the discriminant function, which maximizes the
separation between the two groups of drugs, those that do not induce weight gain (closed circles) and those that do induce weight gain (open circles).
Weights of the variables that comprise the discriminant function are given in Table 5.
Table 5 Coordinates of the variables used for the discriminant
functions analysis in Figure 3
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2002) demonstrated that a polymorphism in the 5-HT2C
gene was highly associated with weight gain induced by
either chlorpromazine or risperidone. Interestingly, both
chlorpromazine and risperidone are rather weak inverse
agonists at h5-HT2C-INI receptors (Rauser et al, 2001), so it
is unlikely that direct interaction of these drugs with 5-HT2C
receptors is important for the weight gain induced by both
drugs. Instead it is more likely that the 5-HT2C polymorph-
ism predisposes individuals to weight gain via an unknown
mechanism.
The mechanism(s) by which H1-histamine antagonism
might induce weight gain are currently unknown, although
prior studies have amply demonstrated that H1-histamine
receptor antagonism increases feeding in rodents whereas
H2-histamine antagonism does not (Sakata et al, 1988;
Fukagawa et al, 1989). Additionally, depletion of neuronal
histamine increases feeding (Menon et al, 1971; Sakai et al,
1995). Interestingly, other psychoactive compounds with
high H1-histamine receptor affinities, for example, ami-
tryptiline (Altamura et al, 1989), have been associated with
significant weight gain. Finally, H1-knockout mice are
relatively resistant to the anorectic actions of leptin, and
are prone to obesity when placed on high-fat diets (Masaki
et al, 2001a, b). Taken together, these results imply that H1-
histamine receptors modulate feeding behavior via a leptin-
dependent mechanism.
It is also clear that mechanisms other than H1-histamine
receptor blockade can also induce weight gain. Thus
sulpiride, a selective D2/D3 antagonist, has virtually no
affinity for H1-histamine receptors (Roth et al, in prepara-
tion), yet it induces significant long-term weight gain
among individuals with schizophrenia (Taylor and McAs-
kill, 2000). Similarly, haloperidol and fluphenazine have
relatively low H1-histamine receptor affinities, yet, when
given in depot formulations, have been reported to induce
substantial weight gain (Taylor and McAskill, 2000). In this
regard, it is interesting to note that the discriminant
functions analysis predicts that fluphenazine will induce
weight gain. Thus, factors independent of H1-histamine
receptor affinity may contribute to weight gain induced by
typical and atypical antipsychotic drugs.
Taken together, these results clearly indicate that anti-
psychotic drugs with high H1-histamine receptor affinities
are associated with significant weight gain. These results are
consistent with the evidence that two of the newer atypical
antipsychotic drugs, ziprasidone and aripiprazole, are
associated with less short-term weight gain. Finally, our
results suggest that since the H1-histamine receptor is the
most likely molecular target responsible for atypical
antipsychotic-drug-induced weight gain, high H1-histamine
receptor affinity should be avoided in the next generation of
multireceptor atypical antipsychotic drug candidates.
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